Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20004774
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\20004774
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Allergy+Clin+Immunol
2009 ; 124
(6
): 1129-38; quiz 1139-40
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Therapy of autoinflammatory syndromes
#MMPMID20004774
Hoffman HM
J Allergy Clin Immunol
2009[Dec]; 124
(6
): 1129-38; quiz 1139-40
PMID20004774
show ga
The therapy of autoinflammatory syndromes is an excellent example of the power of
translational research. Recent advances in our understanding of the molecular and
immunologic basis of this newly identified classification of disease have allowed
for the application of novel, effective, targeted treatments with life-changing
effects on patients. Although colchicine and TNF-alpha inhibitors are important
therapies for specific autoinflammatory syndromes, the novel IL-1-targeted drugs
are particularly effective for many of these diseases. Recently, the
pharmaceutical industry has adopted a strategy of confirming the efficacy of new
targeted drugs in often-ignored patients with orphan diseases, and US Food and
Drug Administration policies have allowed for accelerated approval of these
drugs, creating a win-win situation for patients and industry. This article
reviews the general approach to the therapy of autoinflammatory diseases,
focusing on current approved therapies and novel approaches that might be used in
the future.
free
free
free
